Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Vascular Disease > PE > Flashcards

PE Flashcards

1
Q

What is the years Items

A
  • Pe is more likely diagnosis
  • Unilateral LL edema
  • hemoptysis
    Any positive consider positive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Wells score Cut off

A

More than 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Geneva score

A

More than 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

D -Dimer

A

Normal D-dimer in Low pre-test probability has
100% NPV In patient with high clinical probability, D-Dimer is not
helpful

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

D -Dimer

A

Normal D-dimer in Low pre-test probability has
100% NPV In patient with high clinical probability, D-Dimer is not
helpful

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

D-Dimer for Age

A

Age * 10 if more than 50 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Diagnositc criteria

A

1- CT pulmonary angio
2- V/Q scan
3- Echo in unstable pt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

V/Q scan moditlites in PE ?

A

1- IF Normal negative PE
2 - If V/Q scan yields high probability for PE ( diagnostic )
3- If non diagnostic should be wiht US in PT with Low probability
IF high need further investigation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Chest xray in PE

A

1- Westermark sign
2- Hampton sign

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

High probability of PE CT PE cant be done ? Next step

A

CUS for Proximal DVT if positive no need to go further
If negative further testingneed to be done :-
V/Q scan
IF positive :- no need to go further

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CUS postive3 for PE and used to diagnosis of PE in high probability pt what is the next ?

A

Need to assess pe severity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ECG finding in PE

A

1- S1 Q3 T3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

D-Dimer :-

A

Good -ve and poor +Ve
Sane as clinical scores

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Low and intermediate clincial probability’s , next step

A

D-Dimer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Unstable pt , with high probability of PE , Next step

A

ECHO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PE ruled out criteria (PERC )

A

Age more than 70
Hr moretha 100
Spo2 less than 95
One leg swelling
Hemoptysis
Previuse DVT or PE
Hormone use
Surgery or trauma within last 4 wks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Classification of PE pt
High risk :-

A
  • hemodynamic unstebality
  • PESI score more than or equal one
  • PESI class 3-5
  • RV dysfunction
  • elevated trop T
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Intermediate high risk pt

A

Have postive in PESI score and
RV dysfunction
And Trop T elevated
(Except low BP )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Intermediate high risk pt

A

Have postive in PESI score and
RV dysfunction
And Trop T elevated
(Except low BP )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Intermediate Low

A

PESI score more than or equal one
RV dysfunction OR trop T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Trop T positive and RV dysfunction what is the risk calcification

A

Intermediate high

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

PESI score

A
  • more than 80
  • Cancer
  • cardio- pulmonary disease
  • Hr more than 110
  • BP :- less than 100
  • SPo2 :- less than 90
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Low risk what is the next step ? In mangment

A

NAOC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Intermediate Risk next step in management

A

LMWH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Intermediate high in mangment like high risk

A

True ( need to be reviewed )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Medication during intubation ?

A

Ketamine and etomidate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

PE in respiratory distress , Next step

A

Start with conventional devices
Avoid intubation if possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Ventilation setting in PE

A

Low TV
- low or zero PEEP
- Plateau less than 30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Vasopressors in PE

A

1- NE
Seconde line
Dobutamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

When we have to consider ECMO

A

1- Arrest
2- Bridge to other therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

IVC filter ? Indication

A

1- contraindication of coagualtion
2- PE in adequate anticoag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

PEITHO trail

A

Thromplolysis improved CVS decompansastion in intermediate risk pt but increase the risk of major hemorrhage and stroke

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

PE algorithm

A

Suspected pt :-
1- rule out criteria
2- clinical scores
3- ( D-Dimer or CT PA based on PE probability
4- anticoagulant
5- risk stratification
6- Low risk NAOC
7- high risk :- reperfusion
8- intermediate :-
High :- LMWH and monitor consider reperfusion therapy if deteriorate
Low :- LMWH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Discharge of pt with low risk

A

1- if no other reasons of hospitalization
2- family and social support
3- easy access to medical care
Then discharge if one of them is no then admit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Thrompolysis

A

Molecule Recombinant tissue-type plasminogen
activator (rtPA)
Streptokinase
Regimen
100 mg over 2 h 0.6 mg kg over 15 min
(maximum dose 50 mg) 250,000 IU as a loading dose over 30 min,
followed by 100,000 IU/hover
12-24 h
Accelerated regimen: 1.5 million
IU over 2 h
Contraindications to fibrinolysis
Absolute • History of haemorrhagic stroke or stroke of
unknown origin
• Ischaemic stroke in previous 6 months
• Central nervous system neoplasm • Major trauma, surgery, or head injury in
previous 3 weeks
• Bleeding diathesis
• Active bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Timing of TPA

A

Greatest benefit when initiated within 48 hrs
Can be still used for 6-14 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Failed of thrombolysis

A

Prevelance 8-10 %
Next step
:- repeat
## surgical embolectomey :- I

38
Q

ategorization of risk factors for venous thromboembolism based on the risk of
recurrence over the long-term

A

In PIC

39
Q

Risk Assessment

A

1- RV by image or lab even in low PESI or a PESI of 0

40
Q

In refractory circulatory collapse or cardiac arrest.

A

ECMO may be considered, in combination with surgical embolectomy or catheter-directed treatment,

41
Q

PE with No risk factor / duration of therapy

A

Extended anticoagulation should be considered for patients with no identifiable risk factor for the index PE event.

42
Q

Extended anticoagulation :-

A

1- pt wiht PE and no risk factor
2- in persistent risk factor other than antiphospholipid
3- in minor reversible risk factors

43
Q

A reduced dose of apixaban or rivaroxaban should be considered after the first 6 months.

A
44
Q

Cancer pt / pe management

A

Edoxaban or rivaroxaban should be considered as an alternative to LMWH,
with the exception of patients with gastrointestinal cancer.

45
Q

Pregnant with Low BP , respiratory failure / DIC

A

Amniotic fluid embolism should be considered in a pregnant or post-partum woman, with unexplained haemodynamic instability or respiratory deterioration, and disseminated intravascular coagulation.

46
Q

Pregnant and high risk PE
Management

A

Thrombolysis or surgical embolectomy should be considered for pregnant women with high-risk PE.

47
Q

NOACs are not recommended during pregnancy or lactation.

A
48
Q

Post-PE care and long-term sequelae

A

Routine clinical evaluation is recommended 3- 6 months after acute PE.

An integrated model of care is recommended after acute PE to ensure optimal transition from hospital to ambulatory care.

It is recommended that symptomatic patients with mismatched perfusion defects on a V/Q scan >3 months after acute PE are referred to a pulmonary hypertension/CTEPH expert centre, taking into account the results of echocardiography, natriuretic peptide, and/or cardiopulmonary exercise testing.

49
Q

PE pt in follow up

A

After # month
We have to rule out CTEPH
V/q If mismatch present after 3 Month
Then refer pt for pulmonary hypertension / ECHO

50
Q

Definition of hemodynamic instability

A

1- cardiac arrest
2- obstructive shock :-
SBP less than 90
Or
Vassopresor to keep SBP more than or equal 90
AND :-
END organ hypo perfusion
( Low MS , cold clammy skin , oliguria , increase in lactic acid
3- persistent hypotension
SBp less than 90 OR
More than or equal to 40 drop in SBP
Lasting more than 15 mints
And not caused by new onset arrhythmia
Hypovaemia
Sepsis

One of them

51
Q

V/Q SPECT can be used for PE diagnosis

A
52
Q

CTPA radiation issues

A

Significant radiation exposure to young female breast tissue

53
Q

V/Q scintigraphy

It is recommended to reject the diagnosis of PE (without further testing) if the perfusion lung scan is normal.75,122,134,174

I

A

It should be considered to accept that the diagnosis of PE (without further testing) if the V/Q scan yields high probability for PE.134

IIa

B

A non-diagnostic V/Q scan should be considered as exclusion of PE when combined with a negative proximal CUS in patients with low clinical probability, or who are PE-unlikely

A
54
Q

Further imaging tests to confirm PE may be considered in cases of isolated subsegmental filling defects

A
55
Q

Initiation of anticoagulation is recommended without delay in patients with high or intermediate clinical probability of PE while diagnostic workup is in progress.

A
56
Q

High risk pt anticoagulation

A

It is recommended that i.v. anticoagulation with UFH, including a weight-adjusted bolus injection, be initiated without delay in patients with suspected high-risk PE.

57
Q

PESI SCORE MORE THAN or E 1

A

! 1 point(s) = 30

day mortality risk

10.9%

58
Q

Treatment of right ventricular failure in acute high-risk pulmonary embolism :-

A

Pic

59
Q

Fluid In RV management :-

A

1- less than or E :- 500 cc of RL over 15-30 in CV :- low or normal pressure

60
Q

Fluid In RV management :-

A

1- less than or E :- 500 cc of RL over 15-30 in CV :- low or normal pressure

61
Q

NE

A

Increases RV inotropy and systemic BP, promotes positive ventricular interactions, and restores coronary perfusion gradient

62
Q

NE - side effect

A

Excessive vasoconstriction may worsen tissue perfusion

63
Q

Dobutamine

A

May aggravate arterial hypotension if used alone, without a vasopressor; may trigger or aggravate arrhythmias

64
Q

ECMO side effect

A

Complications with use over longer periods (>5À10 days), including bleeding and infections; no clinical benefit unless combined with surgical embolectomy; requires an experienced team

65
Q

High risk pt first step

A

UFH

66
Q

Percutaneous catheter-directed treatment should be considered for patients with highrisk PE, in whom thrombolysis is contraindicated or has failed

A
67
Q

ECMO may be considered, in combination with surgical embolectomy or catheter-directed treatment, in patients with PE and refractory circulatory collapse or cardiac arrest

A
68
Q

Intermediate Risk anticoagulation

A

If anticoagulation is initiated parenterally, LMWH or fondaparinux is recommended

69
Q

Intermediate Risk anticoagulation

A

If anticoagulation is initiated parenterally, LMWH or fondaparinux is recommended

70
Q

Warfarin management :-

A

When patients are treated with a VKA, overlapping with parenteral anticoagulation is recommended until an INR of 2.5 (range 2 — 3) is reached.

71
Q

NOACs are not recommended in patients with severe renal impairment, d during pregnancy and lactation, and in patients with antiphospholipid antibody syndrome

A
72
Q

Routine use of primary systemic thrombolysis is not recommended in patients with intermediate- or low-risk PE

A
73
Q

For patients with first PE/VTE secondary to a major transient/reversible risk factor, discontinuation of therapeutic oral anticoagulation is recommended after 3 months.

A
74
Q

If extended oral anticoagulation is decided after PE in a patient without cancer, a reduced dose of the NOACs apixaban (2.5 mg b.i.d.) or rivaroxaban (10 mg o.d.) should be considered after 6 months of therapeutic anticoagulation.

A
75
Q

In patients who refuse to take or are unable to tolerate any form of oral anticoagulants, aspirin or sulodexide may be considered for extended VTE prophylaxis

A
76
Q

In patients who receive extended anticoagulation, it is recommended that their drug tolerance and adherence, hepatic and renal ffunction, and bleeding risk be reassessed at regular intervals.

A
77
Q

For patients with PE and cancer, weight-adjusted subcutaneous LMWH should be considered for the first 6 months over VKAs.

A
78
Q

Edoxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH in patients without gastrointestinal cancer

A
79
Q

Rivaroxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH in patients without gastrointestinal cancer

A
80
Q

In patients with cancer, management of incidental PE in the same manner as symptomatic PE should be considered, if it involves segmental or more proximal branches, multiple subsegmental vessels, or a single subsegmental vessel in association with proven DVT.376,377

A
81
Q

Cancer pt GI :-

A

LMWH

82
Q

Pregnancy and PE
Risk factor increase the risk of PE

A

including in vitro fertilization: in a cross-sectional study derived from a Swedish registry, the HR for VTE following in vitro fertilization was 1.77 (95% CI 1.41À2.23) overall and 4.22 (95% CI 2.46À7.20) during the first trimester. 382 Other important and common risk factors include prior VTE, obesity, medical comorbidities, stillbirth, pre-eclampsia, post-partum haemorrhage, and caesarean section; documented risk assessment is therefore essential.

83
Q

Pregnancy and PE
Risk factor increase the risk of PE

A

including in vitro fertilization: in a cross-sectional study derived from a Swedish registry, the HR for VTE following in vitro fertilization was 1.77 (95% CI 1.41À2.23) overall and 4.22 (95% CI 2.46À7.20) during the first trimester. 382 Other important and common risk factors include prior VTE, obesity, medical comorbidities, stillbirth, pre-eclampsia, post-partum haemorrhage, and caesarean section; documented risk assessment is therefore essential.

84
Q

Diagnosis of pulmonary embolism in pregnancy

A

prevalence of confirmed PE is low among women investigated for the disease, between 2 and 7%.

85
Q

PE in pregnancy
High pre test
D- Dimer + in intermediate low risk Next step :-

A

1- LMWH
2 - CXR / US .
US +Ve NExt step :- treat and assess risl of severity and early death
IF not :-
V/q if chest xray normal or CTPA
IF chest xray ubnormal :- CTPA

86
Q

PE in pregnancy
Treatment of choice

A

LMWH is the treatment of choice for PE during pregnancy. 384 In contrast to VKAs and NOACs, LMWH does not cross the placenta, and consequently does not confer a risk of foetal haemorrhage or teratogenicity. Moreover, while UFH is also safe in pregnancy, LMWH has more predictable pharmacokinetics and a more favourable risk profile.

87
Q

PE and pregnancy

Perfusion scintigraphy or CTPA (with a low-radiation dose protocol) should be considered to rule out suspected PE in pregnant women; CTPA should be considered as the first-line option if the chest X-ray is abnormal.385,386

A
88
Q

A therapeutic, fixed dose of LMWH based on early pregnancy body weight is the recommended therapy for PE in the majority of pregnant women without haemodynamic instability

A
89
Q

High risk in pregnancy

A

Thrombolysis or surgical embolectomy should be considered for pregnant women with highrisk PE.4

90
Q

Epidural and PE

A

Insertion of a spinal or epidural needle is not recommended, unless >_24 h have passed since the last therapeutic dose of LMWH.

Administration of LMWH is not recommended within 4 h of removal of an epidural catheter

91
Q

Risk factors and predisposing conditions for chronic thromboembolic pulmonary hypertension44

A

1- Findings related to the acute PE event (obtained at PE diagnosis)

Previous episodes of PE or DVT

Large pulmonary arterial thrombi on CTPA

Echocardiographic signs of PH/RV dysfunctiona

CTPA findings suggestive of pre-existing chronic thromboembolic disease

2- Concomitant chronic diseases and conditions predisposing to CTEPH (documented at PE diagnosis or at 3À6 month follow-up)

Ventriculo-atrial shunts

Infected chronic i.v. lines or pacemakers

History of splenectomy

Thrombophilic disorders, particularly antiphospholipid antibody syndrome and high coagulation factor VIII levels

Non-O blood group

Hypothyroidism treated with thyroid hormones

History of cancer

Myeloproliferative disorders

Inflammatory bowel disease

Chronic osteomyelitis

92
Q

Strategies for patient follow-up after pulmonary embolism

A

Pic

Vascular Disease (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions